El-Shanshory Mohamed, Hablas Nahed Mohammed, Shebel Yasmin, Alhadramy Osama, El-Tahlawi Rehab, Aboonq Moutasem Salih, Soliman Tamer M, Abdel-Gawad Abdelhady Ragab, El Sayed Sayed Mostafa, Abdallah Hesham I, Mahmoud Hany Salah, El-Allaf Hassan, El-Sawy Samer, Yousef Reda S, Abu-El Naga Mostafa, Mariah Reham A, Nabo Manal Mohamed Helmy, Abdel-Haleem Mohamed, Mahmoud Ahmed Alamir, Hassan Mohammad Ahmad, Al Arabi Areej Hesham, Alnakhli Abdullah Ahmed, El Sayed Salah Mohamed
Prophetic Medicine Course and Research Group, Taibah College of Medicine Al-Madinah Al-Munawwarah, Saudi Arabia.
Department of Pediatrics, Tanta University Faculty of Medicine Tanta, Gharbia, Egypt.
Am J Blood Res. 2020 Dec 15;10(6):447-458. eCollection 2020.
Thalassemia is a major health problem in affected children due to iron overload, increased oxidative stress, atherogenic lipid profile and tissue-damage. This study aims at investigating the cardioprotective and tissue-protective benefits of Al-hijamah and their impact on cell-mediated immunity for treating thalassemic children. This study aimed also at investigating the tissue-clearance principle of Taibah mechanism: whenever pathological substances are to be cleared from the human body, Al-hijamah is indicated. Al-hijamah was done to thalassemic children (15 males and 5 females having a mean age of 9.07 ± 4.26 years) using sterile disposable sets in a complete aseptic hospital environment. Prior ethical committee agreement (in addition to written patient's consents) was obtained from Tanta Faculty of Medicine, Egypt. Twenty thalassemic children received iron chelation therapy plus Al-hijamah for one session (30-60 minutes) versus an age and sex-matched thalassemic control group treated with iron chelation therapy only. Al-hijamah is a quite safe outpatient hematological procedure that significantly decreased serum cholesterol (from 129.75 ± 3.67 to 103.5 ± 4.18 mg/dl) and decreased serum triglycerides (from 109.25 ± 8.96 to 91.95 ± 7.22 mg/dl). Interestingly, Al-hijamah exerted significant tissue-protective effects (it decreased serum GPT from 98.65 ± 12.27 to 71.65 ± 32.78 U/L and serum GOT from 96.35 ± 14.33 to 69.35 ± 34.37 U/L). Al-hijamah-induced ferritin excretion caused decreased serum ferritin (high serum ferritin negatively correlated with cell mediated immunity). Al-hijamah exerted cardioprotective and tissue-protective and hypolipidemic effects. Al-hijamah decreased serum cholesterol and is cardioprotective for thalassemic patients as it protects against atherogenesis and atherosclerosis. Medical practice of Al-hijamah is strongly recommended in hospitals. Al-hijamah cleared blood significantly from causative pathological substances e.g. serum ferritin resulting in enhanced cell-mediated immunity (in agreement with the evidence-based Taibah mechanism).
地中海贫血是影响儿童健康的一个主要问题，原因在于铁过载、氧化应激增加、致动脉粥样硬化的脂质谱以及组织损伤。本研究旨在调查拔罐疗法对地中海贫血儿童的心脏保护和组织保护作用及其对细胞介导免疫的影响。本研究还旨在调查塔伊巴机制的组织清除原理：只要需要从人体清除病理物质，就表明需要进行拔罐疗法。在一家完全无菌的医院环境中，使用无菌一次性器械对地中海贫血儿童（15名男性和5名女性，平均年龄9.07±4.26岁）进行拔罐疗法。事先获得了埃及坦塔医学院伦理委员会的同意（以及患者的书面同意书）。20名地中海贫血儿童接受了铁螯合疗法加一次拔罐治疗（30 - 60分钟），与之对照的是年龄和性别匹配的仅接受铁螯合疗法的地中海贫血儿童对照组。拔罐疗法是一种相当安全的门诊血液学操作，可显著降低血清胆固醇（从129.75±3.67降至103.5±4.18毫克/分升）并降低血清甘油三酯（从109.25±8.96降至91.95±7.22毫克/分升）。有趣的是，拔罐疗法具有显著的组织保护作用（它使血清谷丙转氨酶从98.65±12.27降至71.65±32.78 U/L，血清谷草转氨酶从96.35±14.33降至69.35±34.37 U/L）。拔罐疗法引起的铁蛋白排泄导致血清铁蛋白降低（高血清铁蛋白与细胞介导免疫呈负相关）。拔罐疗法具有心脏保护、组织保护和降血脂作用。拔罐疗法可降低血清胆固醇，对地中海贫血患者具有心脏保护作用，因为它可预防动脉粥样硬化和动脉粥样硬化症。强烈建议在医院开展拔罐疗法的医疗实践。拔罐疗法可有效清除血液中的致病性病理物质，如血清铁蛋白，从而增强细胞介导免疫（与基于证据的塔伊巴机制一致）。
